Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Niguarda Hospital

Status and phase

Completed

Phase 2

Conditions

Chronic Lymphocytic Leukemia

Treatments

Drug: Ofatumumab

Drug: Cyclophosphamide

Drug: Pentostatin

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01681563

2010-022332-37 (EudraCT Number)

PCO

Details and patient eligibility

About

This is a phase II multicenter, non-comparative, open label study in older previously untreated Chronic Lymphocytic Leukaemia patients, requiring therapy, aimed at defining the efficacy profile (ORR, CRR and TTP) of pentostatin and cyclophosphamide given in combination with Ofatumumab (PCO).

Full description

Chronic lymphocytic leukemia (CLL) is the most common of the chronic lymphoid leukemias, comprising 30% of all adult leukemias. The majority of CLL patients are of advanced age. Currently, immunochemotherapy with Rituximab, Fludarabine and Cyclophosphamide (RFC) is the standard of care in previously untreated patients with CLL requiring treatment. The combination of Pentostatin and Cyclophosphamide has generated excellent clinical response rates in pretreated B-CLL patients. Early data on the use of Ofatumumab as a single agent in Fludarabine-refractory CLL patients have been reported. Given the reported efficacy of chemo-immunotherapy combinations in CLL and the promising activity and toxicity profile of Pentostatin combinations, we designed a trial of Pentostatin, Cyclophosphamide, and Ofatumumab for previously untreated older patients with CLL. The aim is improving efficacy, in Rituximab resistant CLL, and toxicity considering the good profile of tolerability showed using Ofatumumab as single agent.

Enrollment

47 patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of B-CLL defined by:
1. Circulating lymphocytes of more than or equal to 5 x109/L B lymphocytes (5000/mL) in the peripheral blood for the duration of at least 3 months. AND
2. Flow cytometry confirmation of immunophenotype: CD5, CD19, CD20, CD23, CD79b, and surface Ig
Age ≥ 65 years
Active disease and indication for treatment based on modified NCI-WG guidelines defined by presenting at least any one of the following conditions:
Evidence of progressive marrow failure as manifested by development of, or worsening of anemia and/or thrombocytopenia
Massive (i.e. > 6 cm below the left costal margin) or progressive or symptomatic splenomegaly
Massive nodes (i.e. > 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy
Progressive lymphocytosis with an increase of > 50% over a two month period or an lymphocyte doubling time < 6 months
A minimum of any one of the following disease-related symptoms must be present:
1. Unintentional Weight loss ³ 10% within the previous six months
2. Fevers > 38.0 °C for ≥ 2 weeks without evidence of infection
3. Night sweats for more than 1 month without evidence of infection
Not been previously treated for B-CLL (prior autoimmune hemolytic anemia treatment permitted)
ECOG Performance Status of 0-2
Signed written informed consent prior to performing any study-specific procedures

Exclusion criteria

Prior therapy for B-CLL with any agent except corticosteroids used to treat autoimmune hemolytic anemia
Active autoimmune hemolytic anemia (AIHA) requiring corticosteroid therapy > 100 mg equivalent to hydrocortisone, or chemotherapy
Known Richter transformation
Known CNS involvement of B-CLL
Any radiation therapy ≤ 4 weeks prior to registration;
Any major surgery ≤ 4 weeks prior to registration;
Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C
Past or current malignancy with the exception of basal cell carcinoma of the skin or in situ carcinoma of the cervix or the breast unless the tumor was successfully treated with curative intend at least 2 years prior to trial entry.
Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months prior to Visit 1, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities
History of significant cerebrovascular disease
Glucocorticoid unless given in doses ≤ 100 mg/day hydrocortisone (or equivalent dose of other glucocorticoid) if for exacerbations other than B-CLL (e.g. asthma)
Known HIV positive
Positive serology for Hepatitis B (HB), defined as a positive test for HBsAg. In addition if negative for HBsAg but HBcAb positive and HBsAb negative a HB DNA test will be performed and if positive the subject will be excluded. Note: if HBcAb positive and HBsAb positive, which is indicative of a past infection, the subject can be included.
Screening laboratory values:
1. Creatinine Clearance < 60 mL/min
2. Total bilirubin > 2.0 times upper normal limit (unless due to liver involvement of BCLL)
3. ALT > 3.0 times upper normal limit (unless due to liver involvement of B-CLL)
Treatment with any non-marketed drug substance or experimental therapy within 4 weeks prior to Visit 1 or currently participating in any other interventional clinical study
Known or suspected inability to comply with the study protocol